ACADEMIC RESEARCH IN MODERN SCIENCE
International scientific-online conference
99
THE ROLE OF MELATONIN IN THE PATHOGENESIS AND
TREATMENT OF POLYCYSTIC OVARY SYNDROME
Mahmadullayeva Shahnoza Sodiqjon qizi
PhD student of Tashkent Medical Academy
https://doi.org/10.5281/zenodo.15657360
Annotation
Polycystic ovary syndrome is one of the most common endocrine diseases
in women of reproductive age, a condition characterized by hormonal
imbalance, insulin resistance, inflammation, sleep and mood disorders. Recent
studies have shown that the level of melatonin in follicular fluid is reduced in
women with polycystic ovary syndrome, and in most cases their sleep quality is
impaired.
Objectives
To study and evaluate the effect of melatonin on hormonal balance,
metabolic and reproductive functions in women with polycystic ovary syndrome
and to consider its potential as an additional therapeutic agent in the treatment
process.
Main part
1
. Let's consider the mechanism of action of melatonin:
- Regulation of circadian rhythms: melatonin is synthesized in the pineal
gland and regulates biological rhythms, including the sleep-wake cycle.
- Antioxidant effect: Melatonin neutralizes free radicals, reduces oxidative
stress for the div, and these effects play a key role in the pathogenesis of
polycystic ovary syndrome.
- Regulation of hormonal activity: Melatonin affects the secretion of
gonadotropins and sex hormones and enhances aromatase activity, and at the
same time regulates the level of estrogen.
2.
Clinical significance of melatonin in the course and therapeutic direction
of polycystic ovary syndrome:
- Hormonal balance: Adding melatonin to the treatment plan of women with
polycystic ovary syndrome leads to normalization of testosterone and estrogen
levels and an improvement in the FSG / LG ratio
- Improvement of oocyte and embryo quality: Melatonin can improve the
quality of oocytes and embryos in women with polycystic ovary syndrome,
which can be of great importance in pregnancy planning.
- Reducing the effects of oxidative reactions: The antioxidant activity of
melatonin can help reduce the levels of oxidative factors such as MDA and hs-
CRP.
ACADEMIC RESEARCH IN MODERN SCIENCE
International scientific-online conference
100
- Improving sleep and mood: Melatonin can improve sleep quality and
reduce symptoms of depression and anxiety in women with this syndrome.
3
. How to dose and ensure safety of melatonin.
Safety of use: Melatonin is usually well tolerated by the div when used in
the short term.
Dosage: The recommended dose of melatonin is 5-10 mg per day, the most
optimal time is 30-60 minutes before bedtime.
Contraindications: It is not recommended to use during pregnancy,
breastfeeding, autoimmune diseases and while taking medications that affect
melatonin levels.
4
. Prospects for the use of melatonin in the treatment of polycystic ovary
syndrome
Complementary therapy: Adding melatonin to the treatment plan as a
treatment for polycystic ovary syndrome may be as effective as metformin and
inositol in reducing excess div weight and insulin resistance, which can occur
in more than 80% of women with this syndrome.
Need for further scientific and medical research: Further clinical studies are
needed to confirm the efficacy and safety of long-term use of melatonin in the
treatment of polycystic ovary syndrome.
Conclusion
In short, melatonin has a multifaceted effect, including antioxidant activity,
hormonal regulation, and improving sleep quality. Its use in the treatment of
polycystic ovary syndrome may be promising, but further research is needed to
optimize the dosage and duration of use.
List of used literature:
1.
ICH GCP > реестр клинических исследований США “Эффекты
мелатонина у женшин с СПКЯ”
2.
“Не только гормон сна. Мелатонин и женские болезни” 21 марта 2024
Екатерина Творогова
3.
Медицинский журнал RusMed Сеченовский Университет “Анализ
информативости определения мелатонина при синдроме поликистозных
яичников”
